Similar articles

• A comparison of the respiratory effects of SCH-13949W and isoproterenol aerosols in the treatment of patients with expiratory airflow disorders. Preliminary analysis in a long-term trial in ambulatory patients.

  Cohen BM. Cohen BM. Postgrad Med J. 1971 Mar;47:Suppl:63-71. doi: 10.1136/pgmj.47.550.533. Postgrad Med J. 1971. PMID: 4929396 Clinical Trial. No abstract available.
• The nasal respiratory handicap of expiratory airflow disease: the response to bronchodilator aerosols.

  Cohen BM. Cohen BM. Respiration. 1970;27(4):406-16. doi: 10.1159/000192697. Respiration. 1970. PMID: 4913643 Clinical Trial. No abstract available.
• A comparison of pressure-packed bornchodilator aerosols in chronic obstructive bronchitis.

  Chatterjee SS, Dinda P, Riding WD. Chatterjee SS, et al. Scand J Respir Dis. 1971;52(2):71-6. Scand J Respir Dis. 1971. PMID: 5170643 Clinical Trial. No abstract available.
• Nebulized bronchodilators in obstructive lung disease. II.

  Sheldon GP. Sheldon GP. Ann Allergy. 1972 Feb;30(2):69-85. Ann Allergy. 1972. PMID: 4551435 Review. No abstract available.
• [Current dosed aerosols in the treatment of obstructive airway diseases. 2. Bronchospasmolytics].

  Krecklow B. Krecklow B. Z Arztl Fortbild (Jena). 1984;78(1):5-9. Z Arztl Fortbild (Jena). 1984. PMID: 6231780 Review. German. No abstract available.